Date:8/1/2011

unts payable $
7,136 $
5,569 Accrued expenses,162 3,731 Deferred revenues,670 3,588 Total current liabilities34,968 32,888 Deferred rent2,368 2,397 Deferred income taxes3,703 4,098 Long-term debt21,000 21,000 Other liabilities2,141 2,146 Total liabilities4,180 2,529 Stockholders' equity:Preferred stock-$10.00 par value, 500,000 shares authorized,none issued and outstanding-   -   Common stock-$.01 par value, 175,000,000 shares authorized,,460,782 and 60,807,913 shares issued, respectively5 8 Additional paid-in capital,441 2,548 Accumulated other comprehensive (loss) income(1,545),413 Retained earnings31,037 35,911 Treasury stock, 11,589,603 and 11,596,966 shares at cost (79,883)(79,929)Total stockholders' equity50,655 9,551 Total liabilities and stockholders' equity $
214,835 $
232,080 eResearchTechnology, Inc. and SubsidiariesConsolidated Statements of Cash Flows(in thousands)(unaudited)Six Months Ended June 30,20102011Operating activities:   Net income $
2,578 $
4,874   Adjustments to reconcile net income to net cashprovided by operating activities:Depreciation and amortization,307 2,460 Cost of sales of equipment4 8 Share-based compensation,425 ,421 Deferred income taxes216 413 Loss on disposal of equipment-   780 Changes in operating assets and liabilities:Accounts receivable(1,722)3,648 Inventory(436)(4,973)Prepaid expenses and other(925)(1,761)Accounts payable,227 (1,002)Accrued expenses4,925 (2,624)Income taxes(1,120)(1,288)Deferred revenues2 ,738 Deferred rent(204)23 Net cash provided by operating activities2,377 3,717 Investing activities:   Purchases of property and equipment(8,773)(14,754)   Purchases of investments(999)-     Proceeds from sales of investments,731 -     Payments for acquisitions(80,475)(117)Net cash used in investing activities(79,516)(14,871)Financing activities:   Proceeds from long-term debt23,000 -     Proceeds from exercise of stock options
'/>"/>

SOURCE ERT Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13
Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results